reports
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Tre...
ZURZUVAE® (zuranolone) Receives Positive Opinion from CHMP for the Treatment of Women with Postpartum Depression CAMBRIDGE, Mass., July 25, 2025 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending marketing authorization for ZURZUVAE® (zuranolone) for the treatment of postpartum depression (PPD) in adults following childbirth. If approved by the European Commission (EC), ZURZUVAE will be the first treatment authorized within the European Union specificall...
- Dylan Shindler
- Laura Chico
- Dave Nicoski
- Ross LaDuke
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
NWL NEWELL BRANDS INC
NVR NVR INC.
LEN LENNAR CORPORATION CLASS A
KHC KRAFT HEINZ COMPANY
KBH KB HOME
JACK JACK IN THE BOX INC.
HD HOME DEPOT INC.
CHDN CHURCHILL DOWNS INCORPORATED
CCS CENTURY COMMUNITIES INC.
CAL CALERES INC.
AEO AMERICAN EAGLE OUTFITTERS INC.
DHI D.R. HORTON INC.
BC BRUNSWICK CORPORATION
CRI CARTER'S INC.
GES GUESS? INC.
LEG LEGGETT & PLATT INCORPORATED
SCVL SHOE CARNIVAL INC.
CARS CARS.COM INC.
FT FRANKLIN UNIVERSAL TRUST
MRNA MODERNA INC.
EMBC EMBECTA CORP
- Jonathan Chaplin
AT&T Model Update
We have updated the model following results. Changes to the segments are not material, but changes to capex, cash taxes and free cash flow in light of the OBBBA are. For thoughts following the call, click here. For a review of results, click here. (Rating: Buy; TP: $32; Total Return: +20%).
- Jonathan Chaplin
AT&T quick thoughts following the call 2Q25
In this note we cover evolving thoughts on the implications of the new Cable MVNO, the implications of AT&T’s revised capital allocation decisions, new insights on the pace of fiber deployment, a shift in the FWA strategy, the implications of both for cable, comments on spectrum purchases, the implications for EchoStar, and an early take on mobile and broadband market growth.
- Jonathan Chaplin
AT&T 2Q25 Quick Take: Results strong; FCF guide increased, but less th...
Postpaid phone adds beat estimates, which will come as a relief following Verizon’s results. Service revenue, EBITDA, EPS, and FCF were all slightly better than expected. The Company increased FCF guidance following OBBBA, but by less than some had hoped. In addition, the Company did not commit to increasing share repurchases with the increased FCF.
Kraft Heinz Co: 1 director
A director at Kraft Heinz Co sold 25,000 shares at 27.911USD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
STERIS to Host a Conference Call for Fiscal 2026 First Quarter Results...
STERIS to Host a Conference Call for Fiscal 2026 First Quarter Results on August 7, 2025 DUBLIN, IRELAND, July 22, 2025 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that it will host a conference call to discuss its fiscal 2026 first quarter results at 9:00 a.m. ET on August 7, 2025. The conference call can be heard live at or via phone by dialing 1-833-535-2199 in the United States or 1-412-902-6776 internationally, then asking to join the conference call for STERIS plc. A press release detailing financial results will be issued after the U.S....
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at ...
Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 Lecanemab presentations to include long-term Clarity AD data, real-world treatment insights, and a subcutaneous formulation for continued carePresentations on tau to explore its biological role, the development of targeted therapies and biomarkers, and the future integration of these innovations into clinical practice CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Asso...
Biogen Announces $2 Billion Manufacturing Investment in North Carolina...
Biogen Announces $2 Billion Manufacturing Investment in North Carolina’s Research Triangle Park in Conjunction with its 30th Anniversary Investment builds on Biogen’s 30-year history of manufacturing in the region, with approximately $10 billion invested to date CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BIIB) – today announced it intends to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP). Since breaking ground in 1995, Biogen’s manufacturing in RTP has played a vital role in delivering the compan...
- Dylan Shindler
- Laura Chico
- Wedbush Research
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
BIIB BIOGEN INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
PINS PINTEREST INC. CLASS A
STOK STOKE THERAPEUTICS
SMCI SUPER MICRO COMPUTER
U INC.
VRDN UNITY SOFTWARE
PHVS VIRIDIAN THERAPEUTICS INC
STX PHARVARIS NV
APP SEAGATE TECHNOLOGY HLDGS PLC
TTD APPLOVIN CORP
ATXS THE TRADE DESK
GFS INC.
EWTX ASTRIA THERAPEUTICS INC
GLOBALFOUNDRIES INC
EDGEWISE THERAPEUTICS INC
- Dylan Shindler
- Laura Chico
- Jonathan Chaplin
There is more Cable and Fiber M&A coming
This report provides a detailed update to our fiber forecast, with implications for the Fiber and Cable operators. The analysis suggests a strong incentive for Mobile and Cable operators to continue to consolidate assets. The analysis leverages the latest release of FCC data coupled with new features and data sets that have been built into Broadband Insights.
- Wedbush Research
PEGA PEGASYSTEMS INC.
NBIX NEUROCRINE BIOSCIENCES INC.
BIIB BIOGEN INC.
BCRX BIOCRYST PHARMACEUTICALS INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
CVCO CAVCO INDUSTRIES INC.
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
TTD THE TRADE DESK
INC.
- Dylan Shindler
- Laura Chico
- Jonathan Chaplin
DOJ on spectrum and fourth carrier
The DOJ made some surprising comments on the importance of a fourth carrier and the dangers of the three national carriers acquiring more spectrum in its decision on USM (decision here). Please see Blair’s note for the definitive view on regulatory implications. We provide some quick thoughts on implications for Wireless Carriers and Cable in this brief note.
- Dylan Shindler
- Laura Chico
Biogen and Stoke Therapeutics Announce Presentation of Data from Studi...
Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress – Data from an analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed improvements in cognition and behavior at Week 68 – – These findings support the inclusion of key secondary endpoints assessing cognition and behavior in the Phase 3 EMPEROR study and contrast with outcomes observed in natural history data – CAMBRIDGE, Mass. and BE...
- Wedbush Research
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.